J.&J. to Pay $2.2 Billion in Risperdal Settlement
Tuesday, November 5, 2013 - 01:30
in Health & Medicine
Federal officials said Johnson & Johnson promoted the antipsychotic drug as a way to treat dementia patients for many ailments, when it was only approved for schizophrenia.